May 7, 2026

First pill for obstructive sleep apnea shows promise in third phase of study

Forbes
If a pill from Apnimed, Inc. gets approved by the U.S. Food and Drug Administration, it could give obstructive sleep apnea sufferers another option for treatment. Apnimed announced results from the SynAIRgy phase 3 clinical trial of their AD109 pill. Just over 50% of the study participants who took the once-a-day pill had a reduction in their OSA severity while nearly a quarter, 22.3%, experienced achieved complete OSA control. Those taking AD109 also had improvements in the amount of oxygen they were getting into their blood through their lungs.